| Date | Title | Description |
| 17.09.2026 | Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs | 22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances
LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intel... |
| 10.09.2026 | Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing | SINGAPORE, Sept. 10, 2026 /PRNewswire/ -- Novo Holdings, a leading global healthcare and life sciences investor, today announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd. ("ForYou Medical"), a Chi... |
| 09.09.2026 | Bajaj Finance acquires 5% stake in AI video startup TrueFan AI | Bajaj Finance Limited has acquired a 5% stake in AI-powered video generation platform TrueFan AI as part of Bajaj Finserv’s Finserv Intelligence initiative, which focuses on investments and innovation in emerging technologies.
Advertisment
... |
| 08.09.2026 | SSON Research & Analytics Unveils 2026 Top 20 Most Admired Benchmark Leaders | Shared Services Organizations & Global Business Services ranked on performance - powered by benchmark data
NEW YORK, Sept. 8, 2026 /PRNewswire-PRWeb/ -- SSON Research & Analytics, the research and intelligence arm of the Shared Serv... |
| 02.09.2026 | С первого дубля | С первого дубля Иностранные инновации в фармацевтике появятся в стране через российские копии
С марта 2026 года Минздрав одобрил клинические исследования (КИ) как минимум семи инновационных разработок иностранных компаний, которые только не... |
| 01.09.2026 | Oncology firm Novocure says cyberattack exposed US patient records | Sept 1 : Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patients.
The breach adds to a growing n... |
| 01.09.2026 | Sun Pharma signs deal with US government to reduce drug prices | Drug major Sun Pharmaceutical Industries has signed a deal with the US government to lower prices of its innovative drugs in the US, in line with the lowest prices paid by other developed nations, under the most favoured nation (MFN) pricin... |
| 28.08.2026 | OMNICOM MEDIA OFFICIALLY LAUNCHES HEARTS UNITED | New Agency Brings Together OM's Hearts & Science and Mediahub to Create a New 40-Market Global Network
Hearts United debuts as a leader in new business, outperforming its competitors globally and in EMEA, and topping the US ranking
NEW ... |
| 27.08.2026 | Adaptyv Raises $40 Million Series A As Automated Biology Lab Throughput Grows More Than 5x | Adaptyv has raised $40 million in Series A funding to expand its automated laboratory infrastructure for agentic biology. Highland Europe led the round, with existing investors ACE Ventures, byFounders and Y Combinator increasing their inve... |
| 26.08.2026 | Adaptyv raises $40M to build automated lab for agentic biology |
Adaptyv Biosystems has developed an automated wet lab for rapid experimental validation of newly designed proteins, while drastically reducing the costs per protein. Powered by artificial intelligence, this full-stack platform makes it eas... |
| 24.08.2026 | ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform" | Development of Leptin receptor-based technology and hybrid LNP platform
Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics
... |
| 18.08.2026 | Hims & Hers CEO says FTC lawsuit misunderstands how the company works | Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices.
In an interview with CNBC, he also said the company’s sale of compounded GLP-1 drugs helped to bring pric... |
| 11.08.2026 | Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe | Eli Lilly’s Foundayo won U.K. approval, becoming Europe’s second GLP-1 weight-loss pill and its first approval in the continent
Foundayo will initially be available privately by prescription, with NHS access dependent on a cost-effectivenes... |
| 10.08.2026 | AWS Engineers Move Into Novo Nordisk Lab as Bio Discovery Cuts Coding Barrier | By Brandon Fisher
Published: Aug 10 2026, 1:15 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 06.08.2026 | The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings | Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks.
But while investors cheered Lilly’s results, they punished Novo a day earlier — underscoring a growing divide in Wall Street’s confidence in ... |
| 06.08.2026 | Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and... |
| 05.08.2026 | Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says | Bank of America CEO Brian Moynihan said the company is spending more than $250 million annually to provide GLP-1 weight loss medications to its workforce.
Moynihan told CNBC the expense has surged from zero about five years ago, but called ... |
| 04.08.2026 | Наследство отписали трастам | Наследство отписали трастам Почему владельцы бизнеса не хотят передавать его детям
Владельцы бизнеса все чаще не хотят отдавать компании своим детям. Вместо этого они передают активы трастам, фондам или доверенным лицам. Как пишет The New Y... |
| 01.08.2026 | As Americans go direct with GLP-1 prescriptions, Walmart, Costco, Amazon will be big weight-loss winners | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo
As employers drop GLP-1 coverage, more Americans are being encouraged to use direct-to-consumer (DTC) weight-loss drug prescription programs.
Major retailers and pharmacy ... |
| 31.07.2026 | Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline | Novo Nordisk shares fell after its experimental medicine, ziltivekimab, failed to show a statistically meaningful reduction in major adverse cardiovascular events in patients with certain diseases.
“This does not change our strategic commit... |
| 31.07.2026 | Ziltivekimab Cuts Inflammation, Fails to Cut Heart Attacks: ZEUS Result | By Joseph Blake
Published: Jul 31 2026, 1:08 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 30.07.2026 | Daily Stock Market Live
S&P 500 closes higher Friday as Amazon surges; Dow posts fourth straight winning month: Live updates | The major averages were markedly higher Friday, the last trading session in July, as investors looked past rising bond yields and Amazon shares jumped.
The Nasdaq Composite rose 1% to end at 25,373.85, while the S&P 500 added 0.7% to cl... |
| 24.07.2026 | Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation Thrives | The pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu... |
| 24.07.2026 | Pharma Giants Clash Over GLP-1 Ad Truths | Novo Nordisk launched a major lawsuit against Eli Lilly. It alleges pervasive misleading advertising for Lilly’s prominent GLP-1 drugs, Zepbound and Mounjaro. Novo claims Lilly’s nationwide campaigns leverage outdated clinical trials. They ... |
| 24.07.2026 | Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges | U.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen... |
| 23.07.2026 | Ozempic face? Botox boom boosted by ‘sagging face’ trend, Swiss firm says | The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma’s aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday.
About 10% of U.S. adults now report taking GLP-1 drugs for weight loss, which may... |
| 23.07.2026 | Eli Lilly’s next-generation weight-loss shot clears another hurdle | Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the company said, helping dispel lingering concerns over its potential as it nears regulatory review.
Lilly’s trial... |
| 23.07.2026 | Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials | Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials.
The drug delivered significant weight loss and improvements in a key meas... |
| 22.07.2026 | Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply | Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing.
But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details r... |
| 22.07.2026 | Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads | COPENHAGEN: Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday (Jul 21) it is suing arch US rival Eli Lilly over "false and materially misleading" adverts for its competing weight-loss and anti-diabetes treatments.
The D... |
| 22.07.2026 | Trump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring push | Trump said generic drugs imported into the U.S. will face zero tariffs for two years from August 1.
The rate will rise to 100% in 2028, before doubling a year later.
The latest tariff salvo underscored Trump’s goals of reshoring the low-cos... |
| 21.07.2026 | Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising | Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker’s rival ... |
| 21.07.2026 | Novo Nordisk takes Eli Lilly to court over 'misleading' weight-loss drug ad | Here's what it said | Novo Nordisk said on Tuesday that it had filed a lawsuit against Eli Lilly in a US federal court, accusing the US drugmaker of falsely advertising its weight-loss drugs as being more effective than Novo Nordisk’s treatments.
Novo said in it... |
| 18.07.2026 | Fat cat? Weight-loss drugs may be coming for your overweight pet | Two U.S. biotech companies are testing experimental GLP-1 weight-loss treatments for overweight cats.
It marks one of the earliest attempts to bring the blockbuster drug class into pet medicine.
Analysts say the idea of GLP-1s for animals f... |
| 16.07.2026 | Trouble getting weight loss drugs covered by insurance? Here’s what to know | Getting your Trinity Audio player ready...
By Sydney Lupkin, KFF Health News
A professional in-home caregiver lost her coverage for Zepbound. She soon realized getting it back was not straightforward.
Deborah Finley, 50, of Lodi, California... |
| 12.07.2026 | US Healthcare Landscape Shifts: Access, Innovation, and Political Fault Lines | US healthcare faces unprecedented shifts. ACA enrollment declines amid federal subsidy cuts. Gender-affirming care shrinks under political pressure. Medicare AI causes patient care delays. Abortion access battles intensify over telehealth a... |
| 12.07.2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical giant's ... |
| 11.07.2026 | A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss | Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss.
The biotech company is in the early stages of developing... |
| 11.07.2026 | AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable? | AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years.
Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was... |
| 08.07.2026 | Microsoft Unleashes $2.5 Billion AI Frontier: Reshaping Enterprise Intelligence | Microsoft launched Frontier Company. This new venture commits $2.5 billion. It targets enterprise AI deployment at scale. 6,000 specialized experts will embed with client teams. They will co-design and implement advanced AI systems. Key foc... |
| 08.07.2026 | Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence | Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks
Mean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacy
Up to 84% of weight loss was driven by reducti... |
| 08.07.2026 | Novonesis Invests in TurtleTree to Scale Up Cow-Free Lactoferrin for Early Nutrition | 5 Mins Read Danish biotech giant Novonesis has signed an exclusive deal to scale up and commercialise TurtleTree’s precision-fermented lactoferrin protein, following investment in the Singaporean startup.
Singapore’s TurtleTree has taken a ... |
| 07.07.2026 | Terry Smith dubs weight-loss giant Novo Nordisk ‘investment disaster’ | Star stockpicker Terry Smith has dubbed weight-loss giant Novo Nordisk an “investment disaster” less than two years after he dumped his entire Diageo stake over fears that GLP-1 users would ditch alcohol.
The veteran investment manager, who... |
| 07.07.2026 | BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong - Connecting Global Leaders in Biotechnology | Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.
HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong Kong International Biotechnology Conferenc... |
| 03.07.2026 | Microsoft Launches Frontier Company With $2.5 Billion AI Engineering Investment | Microsoft announced the launch of Microsoft Frontier Company, a new operating business focused on helping enterprise customers deploy AI systems at scale while protecting their proprietary data, workflows, and intellectual property.
The com... |
| 03.07.2026 | Microsoft вложила $2,5 млрд в подразделение по внедрению корпоративного ИИ | Microsoft запустила новое бизнес-подразделение Microsoft Frontier Company, которое будет помогать корпоративным клиентам выбирать, настраивать и внедрять ИИ-инструменты Microsoft и других разработчиков. Компания вложит в проект $2,5 млрд и ... |
| 01.07.2026 | Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Popular — and expensive — GLP-1 weight loss drugs just got a lot cheaper for many older Americans.
Starting Wednesday, the federal government is offering a selection ... |
| 30.06.2026 | Shantha Biologics Announces Cartridge Fill-Finish Collaboration | HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India.
The agreement with Novo ... |
| 30.06.2026 | Medicare will start covering obesity drugs for the first time. Here’s what patients should know | Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge.
The move could unlock a vast new patient population for Novo Nordisk and... |
| 30.06.2026 | 5 Things to Know
SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. As someone with protein coffee in their fridge, I can’t say I’m surprised that “functional beverages” are taking off.
Stock fu... |
| 28.06.2026 | Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet | Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare’s new Bridge demonstration program for a monthly copay of just $50.
But many seniors may be unaware of the landmark shift starting on July 1,... |
| 26.06.2026 | Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo
Novo Nordisk, the maker of Wegovy, introduced its GLP-1 pill for weight loss in early January, while Eli Lilly’s pill, Foundayo, began shipping in April.
In 2025, nearly h... |
| 22.06.2026 | UPS to invest $48 million in temperature-controlled facilities amid healthcare boom | UPS is announcing a new investment in healthcare logistics as demand for the temperature-controlled category booms, CNBC has learned exclusively.
The $48 million investment will go toward improving 27 temperature-controlled facilities acros... |
| 19.06.2026 | What this biotech’s volatile stock price tells you about the weight loss market right now | Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company’s obesity strategy
While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide
An e... |
| 19.06.2026 | U.S. opens tariff probe targeting Germany’s drug pricing policies | The U.S. said the probe will examine whether “persistent underpayment” for medicines by Germany is discriminatory.
“President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceu... |
| 17.06.2026 | Hacking group claims major hack of Novo Nordisk and attempted US$25 million extortion | A cyber extortion group claimed on Tuesday (Jun 16) to have stolen more than a terabyte of data from pharmaceutical giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding US$25 million from the ... |
| 16.06.2026 | Biotech IPO revival faces competition from cash-rich big pharma buyers | Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan’s top EMEA healthcare investment bankers told CNBC.
Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simu... |
| 16.06.2026 | Colorado receives FDA permission to import cheaper drugs — including Ozempic — from Canada | Getting your Trinity Audio player ready...
Colorado finally has federal permission to start importing cheaper prescription drugs from Canada, but the state may not have any sellers to work with.
Lawmakers passed a bill in 2019 that directed... |
| 16.06.2026 | Biocon eyes crown of world’s top insulin supplier amid rush for GLP-1 | Mumbai: Indian drugmaker Biocon Ltd. is aiming to become the world’s top supplier of insulin in the coming years, co-founder Kiran Mazumdar-Shaw said, by capturing growing demand for the critical diabetes drug while Big Pharma shifts its fo... |
| 13.06.2026 | Drugmakers race to find a place in the next wave of obesity drugs | Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine.
Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scient... |
| 12.06.2026 | Telehealth booms as demand for GLP-1s surges and questions mount about safety, oversight | Getting your Trinity Audio player ready...
By Lauren Sausser and Maia Rosenfeld, KFF Health News
Within 24 hours of injecting the first dose of a weight loss medication she received following a visit with a telehealth doctor, Karleigh McCla... |
| 12.06.2026 | Mendo Raises €12 Million Series A To Accelerate Enterprise GenAI Adoption | Mendo announced that it has raised €12 million in Series A funding in a round led by Educapital, Ventech, TOMCAT, and OVNI Capital.
The company said the new funding will support its mission of helping enterprises achieve measurable and huma... |
| 11.06.2026 | Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Rega... | Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association... |
| 09.06.2026 | Открытое использование (public domain): когда истекает патент и как работать с общественным достоянием | Патент — это временная монополия. Государство даёт изобретателю исключительное право на коммерческое использование технологии в обмен на ее публичное раскрытие. Когда срок действия данного права истекает, технология переходит в общественное... |
| 04.06.2026 | GPT-Rosalind Drug Discovery Update: OpenAI Cuts Genomics Compute, Expands Global Access | By Shannon Harwood
Published: Jun 04 2026, 06:55 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 02.06.2026 | NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapore | The collaboration aims to improve access to lifestyle coaching supported, clinically guided programs for patients exploring medical weight care.
SINGAPORE, June 2, 2026 /PRNewswire/ -- NOVI Health today announced a strategic partnership wit... |
| 29.05.2026 | Food brands prepare to follow GLP-1 users on and off the drugs | Just a few years ago, some food makers planned to wait around for GLP-1 users drop off the weight-loss medications and revert to their usual eating habits, Gali Artzi said recently. Today that thinking is toast.
Artzi, the chief technology ... |
| 28.05.2026 | CVS to restore coverage of Zepbound, add Eli Lilly’s obesity pill to drug plans | CVS Health said it will restore coverage of Eli Lilly’s blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans.
The move supports Lilly’s efforts to maintain its dominance over Novo Nor... |
| 26.05.2026 | Game-changing accelerator which has helped life science start-ups raise £120m welcomes new cohort | Six exciting early-stage ventures secure coveted spots on Babraham Research Campus’ Accelerate@Babraham pre-seed company support programme.
Cambridge, UK, 26th May 2026: Babraham Research Campus is delighted to announce the 2026 Accelerate@... |
| 23.05.2026 | Новый экспериментальный препарат для похудения обеспечил резкое снижение веса | По данным компании Eli Lilly, участники исследования, которым вводили препарат ретатрутид, через 80 недель в среднем сбросили 28 процентов своей массы тела.
Экспериментальный препарат помог участникам крупного клинического испытания похудет... |
| 21.05.2026 | Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings | SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company" or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against th... |
| 21.05.2026 | Eli Lilly says next-generation weight loss drug clears crucial obesity trial | Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses.
The results bring Lilly one step closer to filing for approval of the weekly injection, ca... |
| 19.05.2026 | Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global P... | CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and... |
| 18.05.2026 | Alcolase: €1.5 Million Raised For Enzyme-Based Remedy Addressing Alcohol Intolerance | Ada Ventures announced it has co-led a €1.5 million funding round into Danish-British biotech company Alcolase, which is developing what it describes as the world’s first enzyme system designed to break down alcohol in the stomach before it... |
| 18.05.2026 | White House adds generic drugs to direct-to-consumer TrumpRx site | The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx.
The platform, which launched in February, is key to his administration’s efforts to lower prescription drug cost... |
| 18.05.2026 | Weight-loss wars go global as Novo Nordisk bets big on its Wegovy pill | Novo Nordisk sees a “major opportunity” outside of the U.S. and says that telehealth partners could help grow the global market for weight loss drugs.
The battle for dominance over the lucrative market has so far focused largely on the key ... |
| 12.05.2026 | Hims & Hers plummets 13% after first-quarter loss, weak earnings guidance | Digital health firm Hims & Hers’ stock plummeted on Tuesday on weak first-quarter earnings.
Hims reported a net loss of $92 million in the first quarter, up from $50 million last year.
The company recently reached an agreement with Novo... |
| 12.05.2026 | Asia’s trillion-dollar titans are powering — and distorting — its fastest growing stock markets | Taiwan’s Taiex and South Korea’s Kospi stock markets have been seeing record-breaking rallies.
Heavy reliance on semiconductor giants raised fears of market concentration.
TSMC now accounts for over 40% of the Taiex benchmark, while Samsung... |
| 11.05.2026 | Caliber Launches Talent Intelligence Platform Talent 360 | Caliber Launches Talent Intelligence Platform Talent 360
Mon, May 11, 2026 12:00 CET Report this content
The first talent intelligence platform built for the AI era, Talent 360 gives CHROs, People & Culture leaders, and Talent Acquisiti... |
| 07.05.2026 | Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2... |
| 07.05.2026 | 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensiv... | SUZHOU, China, May 7, 2026 /PRNewswire/ -- Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") announced that its proprietary GLP-1 (glucagon-like... |
| 04.05.2026 | CNBC Daily Open: As Gulf fatigue sets in, earnings take center stage | Trump launched the “Project Freedom” to free cargo ships stranded in the Strait of Hormuz.
Oil markets were not too impressed by the Middle East noise.
Most Asian indexes traded higher, with Kospi notching a fresh record high.
Spirit Airlin... |
| 04.05.2026 | ‘Bubble effect’: Weight loss drug fueled growth is putting the pharma sector at risk, report finds | For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, Deloitte has found.
Pharma R&D returns for the world’s top 20 pharma companies have improved for a third year straight to 7%, dr... |
| 22.04.2026 | 5 Things to Know
Ceasefire extension, Best Buy’s new CEO, Amazon’s GLP-1 push and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Wednesday. With all the volatility in the oil market, I found it helpful to look at this timeline for a reminder of all that’s happened... |
| 21.04.2026 | UnitedHealth tops quarterly estimates, hikes profit outlook as insurer manages high medical costs | UnitedHealth Group on Tuesday posted first-quarter earnings that topped Wall Street estimates for both revenue and earnings per share.
The company hiked its 2026 profit outlook as it better manages high medical costs and streamlines operati... |
| 21.04.2026 | This biotech firm has room to run despite surging nearly 500% in past year, Morgan Stanley says | - |
| 21.04.2026 | Amazon launches GLP-1 weight loss program, promising ‘fast, convenient’ access | Amazon One Medical launched a GLP-1 program integrating obesity care with Amazon Pharmacy.
Pricing for the popular weight loss drugs will begin at as low as $25 per month with insurance.
Shares of Hims & Hers Health, Viking Therapeutics... |
| 17.04.2026 | World Hemophilia Day 2026 - April 17, 2026 - "Diagnosis: First step to care." | MONTREAL, April 17, 2026 /PRNewswire/ -- On April 17, 2026, the global inherited bleeding disorders community will come together on World Hemophilia Day to advocate for all inherited bleeding disorders. This year's theme of "Diagnosis:... |
| 16.04.2026 | Inside India newsletter: Small towns are powering e-commerce’s fastest-growing market, dominated by Amazon, Walmart unit | Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET
India’s e‑commerce market saw a compound annual growth of 23% between 2020 and 2025 — the world’s fastest.
30% of Indians shopped online in 2025, far behind China (92%) and the U.S. (... |
| 08.04.2026 | CNBC’s UK Exchange newsletter: Brace yourself for rising bills as new tax year kicks off | The new tax year has kicked off in the U.K.
Households and businesses are facing rising bills due to a range of measures introduced by the Labour government.
There will be some winners with mobile and broadband suppliers and water companies... |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 04.04.2026 | Asian travelers seek respite in other options as Middle East travel plans stay grounded | Asian travelers reconsider their vacation plans due to rising airfare and safety concerns.
Last minute airfare changes are cited as the biggest reason for cancellations, experts say.
Cruises and alternative locations in the region have beco... |
| 03.04.2026 | Foundayo Arrives: Eli Lilly's Pill Set to Transform Weight Loss | Eli Lilly's Foundayo receives swift FDA approval. This daily oral GLP-1 pill targets obesity, expanding treatment options. Foundayo offers convenience and improved health outcomes, albeit with less weight loss than injectables. Competitive ... |
| 03.04.2026 | GLP-1 Revolution: Novo Nordisk Innovates Pricing, Expands Health Impact | Novo Nordisk aggressively reshapes the GLP-1 landscape. It launches multi-month Wegovy subscriptions in the U.S., ensuring predictable pricing and bolstering patient adherence against Eli Lilly's market dominance. Concurrently, the UK's NIC... |
| 02.04.2026 | 5 Things to Know
Trump’s address, SpaceX IPO, Sam’s Club membership prices and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Thursday. It’s the one-year anniversary of President Donald Trump’s initial tariff unveiling, what the president dubbed “liberation day... |
| 02.04.2026 | Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t cheap. Related Articles
Trump has private... |
| 02.04.2026 | Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs | The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned.
The Trump administration is... |
| 02.04.2026 | Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison | Oral Wegovy demonstrated “significantly greater mean weight loss” than Lilly’s rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday.
Novo’s findings evaluated previously published studies of the medicines and did no... |
| 02.04.2026 | Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions | Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions.
The presentati... |
